Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
04/2003
04/03/2003CA2461360A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
04/03/2003CA2461095A1 Process for making substituted pyrazoles
04/03/2003CA2460953A1 Proteins associated with cell growth, differentiation, and death
04/03/2003CA2456281A1 Pyrane derivatives as both ace- and nep- inhibitors
04/03/2003CA2453985A1 Receptors and membrane-associated proteins
04/02/2003EP1297137A2 Gp286 nucleic acids and polypeptides
04/02/2003EP1297129A2 Card domain containing polypeptides, encoding nucleic acids, and methods of use
04/02/2003EP1297014A2 Transporters and ion channels
04/02/2003EP1296990A2 Dihydropyridine compounds for the inhibition of calcium-influx
04/02/2003EP1296976A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
04/02/2003EP1296961A1 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
04/02/2003EP1296956A1 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
04/02/2003EP1296948A2 Novel gamma crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
04/02/2003EP1296947A1 $g(A) CRYSTALLINE FORM OF PERINDOPRIL TERT-BUTYLAMINE SALT
04/02/2003EP1296943A1 Amino acid derivatives and their use as medicines
04/02/2003EP1296934A1 Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
04/02/2003EP1296929A2 Modified forms of pharmacologically active agents and uses therefor
04/02/2003EP1296716A2 New formulation
04/02/2003EP1296702A1 Neuroprotective peptides
04/02/2003EP1296552A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5
04/02/2003EP1114051B1 INHIBITORS OF p38
04/02/2003EP1043993B1 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents
04/02/2003EP0954519B1 Alpha-9 integrin antagonists and anti-inflammatory compositions therof
04/02/2003EP0894089B9 Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
04/02/2003CN1407986A Novel imidazotriazinones and the use thereof
04/02/2003CN1407985A Heterocyclic dihydropyrimidine as potassium path inhibitor
04/02/2003CN1407984A 1,8-naphthyridin-2 (1H)-one derivatives
04/02/2003CN1407980A Heterocyclic derivatives
04/02/2003CN1407971A Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
04/02/2003CN1407970A Urea compounds having muscarinic receptor antagonist activity
04/02/2003CN1406623A Levulose absorption retardant, compound, food and levulose absorption repressor
04/02/2003CN1104440C Method for variation of chromatin condensation
04/02/2003CN1104432C Pyrrole triazines and pyrimidine compound
04/02/2003CN1104422C Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
04/02/2003CN1104421C Novel imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
04/02/2003CN1104418C Benzoheterocyclic derivatives
04/01/2003US6541669 Multibinding amine compounds which are beta 2 adrenergic receptor agonists useful in treatment and prevention of respiratory diseases such as asthma, bronchitis
04/01/2003US6541638 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction
04/01/2003US6541605 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
04/01/2003US6541508 Water solubility; prodrug containing polyether oligomer
04/01/2003US6541503 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
04/01/2003US6541489 Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1
04/01/2003US6541463 Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use
04/01/2003CA2102129C Growth hormone antagonists
03/2003
03/31/2003WO2002030425A1 Preventives and remedies for complications of diabetes
03/31/2003CA2424060A1 Preventives and remedies for complications of diabetes
03/27/2003WO2003025542A2 Immune response associated proteins
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025178A1 Novel protein and dna thereof
03/27/2003WO2003025168A1 Novel protein and dna thereof
03/27/2003WO2003025017A1 Cytokine receptor
03/27/2003WO2003024993A2 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
03/27/2003WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity
03/27/2003WO2003024948A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
03/27/2003WO2003024924A1 Novel compounds and compositions as cathepsin inhibitors
03/27/2003WO2003024922A1 Hydroxyfattysulfonic acid analogs
03/27/2003WO2003024916A1 Crystals of hydroxynorephedrine derivative
03/27/2003WO2003024483A1 Potentiator for inhibitory effects on urinary frequency and urinary incontinence
03/27/2003WO2003024465A2 Use of extracts of the genus cimicifuga as organoselective medicines
03/27/2003WO2003024444A1 Combination of selected opioids with muscarine antagonists for treating urinary incontinence
03/27/2003WO2003024402A2 Lpa receptor agonists and antagonists and methods of use
03/27/2003WO2003024395A2 Linked biaryl compounds
03/27/2003WO2003024390A2 Hydroxyeicosenoic acid analogs
03/27/2003WO2003024386A2 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
03/27/2003WO2003002553A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
03/27/2003WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002060859A3 Cyclic derivatives as modulators of chemokine receptor activity
03/27/2003WO2002040506A3 Modified clostridial neurotoxins with altered biological persistence
03/27/2003WO2002028844A1 Thiazole or oxazole derivatives
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003US20030060627 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives
03/27/2003US20030060619 Antibody for use in the disgnosis and treatment of kidney, urogenital, and sex disorders
03/27/2003US20030060497 Use of indole Mannich bases in the production of medicaments that are used to treat pain
03/27/2003US20030060490 Method for the treatment and prevention of urinary stone disease
03/27/2003US20030060459 Diamines as modulators of chemokine receptor activity
03/27/2003US20030060452 N-heterocyclic derivatives as NOS inhibitors
03/27/2003US20030060410 Use of HMG fragments as anti-inflammatory agents
03/27/2003US20030060401 Genetic engineered drug
03/27/2003US20030060399 A heat shock protein 20 (HSP20)-derived polypeptides for treating or inhibiting smooth muscle vasospasm, smooth muscle cell proliferation, migration, and vasoconstriction
03/27/2003US20030059862 Antibodies against tumor necrosis factor delta (APRIL)
03/27/2003US20030059767 Zinc finger protein derivatives and methods therefor
03/27/2003CA2460845A1 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
03/27/2003CA2460808A1 Immune response associated proteins
03/27/2003CA2460358A1 Hydroxyfattysulfonic acid analogs
03/27/2003CA2460319A1 Lpa receptor agonists and antagonists and methods of use
03/27/2003CA2460263A1 Hydroxyeicosenoic acid analogs
03/27/2003CA2460151A1 Cytokine receptor
03/27/2003CA2460125A1 Novel compounds and compositions as cathepsin inhibitors
03/27/2003CA2459454A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
03/27/2003CA2423885A1 Thiazole and oxazole derivatives
03/26/2003EP1295939A1 Insulin-like growth factor binding protein
03/26/2003EP1295870A1 Suplatast tosilate crystals
03/26/2003EP1294905A1 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
03/26/2003EP1294882A2 B7-like molecules and uses thereof
03/26/2003EP1294874A2 Cd154 variants and uses thereof
03/26/2003EP1294871A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof
03/26/2003EP1294856A1 DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE
03/26/2003EP1294765A2 Il-17 molecules and uses thereof
03/26/2003EP1294754A1 Interferon-alpha induced gene
1 ... 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 ... 562